Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
We have constructed novel live attenuated herpes simplex virus (HSV) vaccines. The constructed vaccines exhibited more vaccine efficacy than a control live attenuated HSV vaccine, TK-deficient mutant virus. In addition, we identified novel HSV proteins that inhibit host immune responses. One of the HSV proteins inhibited induction of proinfalamatory cytokines, which are known to control HSV infection in vivo, by interacting with a host cellular protein that regulates the induction of the proinflamatory cytokines.
|